Literature DB >> 12480899

Infection of myocytes with chlamydiae.

Guqi Wang1, Frank Burczynski1, Brian Hasinoff1, Guangming Zhong2.   

Abstract

Chlamydial infection has been associated with myocarditis in animals and humans. However, the mechanism resulting in myocarditis following infection is not known. Here, evidence is presented that both Chlamydia trachomatis and Chlamydia pneumoniae can infect and replicate in myocytes isolated from neonate rats. The infected myocytes contained chlamydial inclusions, indicative of chlamydial growth, and infectious particles were recovered from the infected myocytes. It was also found that chlamydial infection at a late stage induced significant damage to the infected myocytes, as evidenced by an increased lactate dehydrogenase release, reactive oxygen species production and a reduced ATP level. However, no nuclear apoptosis was detected in the infected myocytes. Collectively, these observations have demonstrated that Chlamydia spp. are able to both infect and damage myocytes, suggesting a potential role of chlamydial infection in myocarditis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480899     DOI: 10.1099/00221287-148-12-3955

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  10 in total

1.  Persistent Chlamydia pneumoniae infection of cardiomyocytes is correlated with fatal myocardial infarction.

Authors:  Luigi Giusto Spagnoli; Sabina Pucci; Elena Bonanno; Antonio Cassone; Fabiola Sesti; Alessandra Ciervo; Alessandro Mauriello
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

2.  Effect of Chlamydia pneumoniae on cellular ATP content in mouse macrophages: role of Toll-like receptor 2.

Authors:  Kambiz Yaraei; Lee Ann Campbell; Xiaodong Zhu; W Conrad Liles; Cho-Chou Kuo; Michael E Rosenfeld
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Incidence of cardiovascular events after hospital admission for pneumonia.

Authors:  Theodore W Perry; Mary Jo V Pugh; Grant W Waterer; Brandy Nakashima; Carlos J Orihuela; Laurel A Copeland; Marcos I Restrepo; Antonio Anzueto; Eric M Mortensen
Journal:  Am J Med       Date:  2011-03       Impact factor: 4.965

4.  Chlamydophila pneumoniae myopericarditis in a child.

Authors:  Monnipa Suesaowalak; Michele M Cheung; Dawn Tucker; Anthony C Chang; James Chu; Antonio Arrieta
Journal:  Pediatr Cardiol       Date:  2008-10-25       Impact factor: 1.655

5.  Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatin.

Authors:  Yuriy K Bashmakov; Nailya A Zigangirova; Yulia P Pashko; Lidia N Kapotina; Ivan M Petyaev
Journal:  Comp Hepatol       Date:  2010-01-28

6.  Chlamydia trachomatis-infected epithelial cells and fibroblasts retain the ability to express surface-presented major histocompatibility complex class I molecules.

Authors:  Danny Kägebein; Melanie Gutjahr; Christina Große; Annette B Vogel; Jürgen Rödel; Michael R Knittler
Journal:  Infect Immun       Date:  2013-12-16       Impact factor: 3.441

7.  Pneumonia: an arrhythmogenic disease?

Authors:  Natalia Soto-Gomez; Antonio Anzueto; Grant W Waterer; Marcos I Restrepo; Eric M Mortensen
Journal:  Am J Med       Date:  2012-11-20       Impact factor: 4.965

8.  Predictors and outcomes of infection-related hospital admissions of heart failure patients.

Authors:  Danny Alon; Gideon Y Stein; Roman Korenfeld; Shmuel Fuchs
Journal:  PLoS One       Date:  2013-08-23       Impact factor: 3.240

9.  The association of cardioprotective medications with pneumonia-related outcomes.

Authors:  Albert Wu; Chester Good; John R Downs; Michael J Fine; Mary Jo V Pugh; Antonio Anzueto; Eric M Mortensen
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

10.  Association of Chlamydia trachomatis, C. pneumoniae, and IL-6 and IL-8 Gene Alterations With Heart Diseases.

Authors:  Nubia Caroline Costa Almeida; Maria Alice Freitas Queiroz; Sandra Souza Lima; Igor Brasil Costa; Marco Antonio Ayin Fossa; Antonio Carlos R Vallinoto; Marluísa de Oliveira Guimarães Ishak; Ricardo Ishak
Journal:  Front Immunol       Date:  2019-02-05       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.